Van KempenZLLeursCEWitteBLet al. The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing. Mult Scler2018; 24: 805–810.
2.
KhatriBOManSGiovannoniGet al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology2009; 72: 402–409.
3.
O’ConnorP.Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis. Expert Opin Biol Ther2007; 7: 123–136.
4.
SehrTProschmannUThomasKet al. New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies. J Neuroinflammation2016; 13(1): 164.
5.
TanakaMKinoshitaMFoleyJFet al. Body weight-based natalizumab treatment in adult patients with multiple sclerosis. J Neurol2015; 262(3): 781–782.
6.
FoleyJFMetzgerRHoytTet al. The effect of dosing interval extension and patient weight on long term natalizumab pharmacokinetics. Neurology2015; 84(Suppl. 14): 3.258.
7.
MuralidharanKKKuestersGPlavinaTet al. Population pharmacokinetics and target engagement of natalizumab in patients with multiple sclerosis. J Clin Pharmacol. Epub ahead of print 11April2017. DOI: 10.1002/jcph.894.
8.
HarrerAOppermannKPilzGet al. Flow cytometry and drug-monitoring of natalizumab saturation of immune cells in multiple sclerosis. Laboratoriums Medizin2013; 36(6): 377–382.
9.
HarrerAPilzGOppermannKet al. From natalizumab to fingolimod in eight weeks—Immunological, clinical, and radiological data in quest of the optimal switch. Clin Immunol2017; 176: 87–93.
